section name header

Information

Type 1 is an autosomal dominant disorder with genetic anticipation. Weakness typically becomes obvious in the second to third decade and initially involves the muscles of the face, neck, and distal extremities. This results in a distinctive facial appearance (“hatchet-faced”) with ptosis, temporal wasting, drooping of the lower lip, and sagging of the jaw. Myotonia manifests as an inability to relax muscles rapidly following a strong exertion (e.g., after tight hand grip) usually by the age of 5, and by sustained contraction of muscles following percussion (e.g., of tongue or thenar eminence).

Associated findings can include frontal baldness, posterior subcapsular cataracts, gonadal atrophy, respiratory and cardiac problems, endocrine abnormalities, intellectual impairment, and hypersomnia. Cardiac disturbances, including complete heart block, may be life-threatening. Respiratory function should be carefully followed, as chronic hypoxia may lead to cor pulmonale.

Laboratory studies show normal or mildly elevated CK, characteristic myotonia and myopathic features on EMG, and a typical pattern of muscle fiber injury on biopsy, including selective type 1 fiber atrophy in 50% of cases. Myotonic dystrophy type 1 is caused by an unstable expansion of a CTG trinucleotide repeat in a protein kinase gene (named DMPK) on chromosome 19q13.3. Genetic testing for early detection and prenatal diagnosis is possible.

Treatment: Myotonic Dystrophy

  • Phenytoin or mexiletine may help alleviate myotonia, although pts are rarely bothered by this symptom.
  • Pacemaker insertion may be required for syncope or heart block.
  • Orthoses may control foot drop, stabilize the ankle, and decrease falls.
  • Excessive daytime somnolence with or without sleep apnea is not uncommon; sleep studies, noninvasive respiratory support (BiPAP), and treatment with modafinil may be beneficial.

Outline

Section 14. Neurology